Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?

被引：0
|
作者：
Gupta V. [1 ]
Ramirez M.C. [1 ]
Schauser L. [1 ]
机构：
[1] QIAGEN, India
来源：
Genetic Engineering and Biotechnology News | 2019年 / 39卷 / 06期
关键词：
3;
D O I：
10.1089/gen.39.06.19
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：56 / 57
页数：1
相关论文
共 50 条
  • [31] PD-L1 testing in triple negative breast cancer
    Dobritoiu, F.
    Chefani, A.
    Billingham, K.
    Chenard, M.
    Vaziri, R.
    Lacroix-Triki, M.
    Waydelich, A.
    Erb, G.
    Toro, P.
    Wedden, S.
    D'Arrigo, C.
    VIRCHOWS ARCHIV, 2019, 475 : S17 - S18
  • [32] TAPping Into PD-L1 Testing Efficiency for Gastroesophageal Cancer
    Henick, Brian S.
    Moy, Ryan H.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [33] PD-L1 testing by immunohistochemistry in immuno-oncology
    Vranic, Semir
    Gatalica, Zoran
    BIOMOLECULES AND BIOMEDICINE, 2023, 23 (01): : 15 - 25
  • [34] Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer
    Mitchell, Kyle G.
    Negrao, Marcelo V.
    Parra, Edwin R.
    Li, Jun
    Zhang, Jianhua
    Dejima, Hitoshi
    Vaporciyan, Ara A.
    Swisher, Stephen G.
    Weissferdt, Annikka
    Antonoff, Mara B.
    Cascone, Tina
    Roarty, Emily
    Wistuba, Ignacio I.
    Heymach, John V.
    Gibbons, Don L.
    Zhang, Jianjun
    Sepesi, Boris
    ANNALS OF THORACIC SURGERY, 2020, 109 (02): : 358 - 366
  • [35] Reply to: Problems With the Recommendations for PD-L1 Biomarker Testing
    Torlakovic, Emina E.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (07) : E65 - E67
  • [36] The Role of PD-L1 Testing in Advanced Genitourinary Malignancies
    Hahn, Andrew W.
    Sirohi, Deepika
    Agarwal, Neeraj
    EUROPEAN UROLOGY FOCUS, 2020, 6 (01): : 11 - 13
  • [37] PD-L1 testing in urothelial carcinoma: are we there yet?
    van Leenders, Geert J. L. H.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S466 - S468
  • [38] PD-L1 and Tumor Mutational Burden Are Not Predictive of Thrombosis in a Cohort of 1,221 Patients with Solid Organ Malignancies
    Thawani, Rajat
    Kartika, Thomas
    Elstrott, Benjamin
    Batiuk, Elizabeth
    Chen, Lilian
    Tun, Nattapron
    Taflin, Nicholas
    Tao, Derrick Law
    West, Malinda T.
    Shatzel, Joseph J.
    BLOOD, 2021, 138
  • [39] Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
    Schatz, Stefanie
    Falk, Markus
    Jori, Balazs
    Ramdani, Hayat O.
    Schmidt, Stefanie
    Willing, Eva-Maria
    Menon, Roopika
    Groen, Harry J. M.
    Diehl, Linda
    Kroeger, Matthias
    Wesseler, Claas
    Griesinger, Frank
    Hoffknecht, Petra
    Tiemann, Markus
    Heukamp, Lukas C.
    CANCERS, 2020, 12 (06) : 1 - 14
  • [40] Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Morrison, Carl
    Pabla, Sarabjot
    Conroy, Jeffrey M.
    Nesline, Mary K.
    Glenn, Sean T.
    Dressman, Devin
    Papanicolau-Sengos, Antonios
    Burgher, Blake
    Andreas, Jonathan
    Giamo, Vincent
    Qin, Moachun
    Wang, Yirong
    Lenzo, Felicia L.
    Omilian, Angela
    Bshara, Wiam
    Zibelman, Matthew
    Ghatalia, Pooja
    Dragnev, Konstantin
    Shirai, Keisuke
    Madden, Katherine G.
    Tafe, Laura J.
    Shah, Neel
    Kasuganti, Deepa
    de la Cruz-Merino, Luis
    Araujo, Isabel
    Saenger, Yvonne
    Bogardus, Margaret
    Villalona-Calero, Miguel
    Diaz, Zuanel
    Day, Roger
    Eisenberg, Marcia
    Anderson, Steven M.
    Puzanov, Igor
    Galluzzi, Lorenzo
    Gardner, Mark
    Ernstoff, Marc S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345